Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 0.56 |
| ▸ | RARG | P13631 | 17/20 | 0.56 |
| ▸ | RARA | P10276 | 13/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.46 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374116 | 0.93 | RARB (0.66) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL8620103 | 0.84 | RARB (0.46) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL8617050 | 0.83 | RARA (0.51) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL8620351 | 0.82 | RARA (0.49) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL8620109 | 0.82 | RARA (0.48) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6378001 | 0.82 | RARA (0.65) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL8620348 | 0.80 | RARB (0.42) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL8615155 | 0.80 | RARA (0.49) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7753714 | 0.79 | RARG (0.79) | RARBRARGRARACYP3A4MEN1 | |
| SCHEMBL8616987 | 0.79 | RARA (0.65) | RARBRARGRARACYP3A4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686386-B1 | COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-03 | — | — | US | claimed |
| US-6593359-B1 | Pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating gamma -RAR receptors is disclosed. | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-07-15 | — | — | US | claimed |
| US-20010018456-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | FESUS LASZLO (HU) | 2001-08-30 | — | — | US | claimed |
| US-20050112123-A1 | Methods of treating proteinuria | WASHINGTON, UNIVERSITY OF | 2005-05-26 | — | — | US | disclosed |
| US-6686386-B1 | COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-03 | — | — | US | disclosed |
| US-6593359-B1 | Pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating gamma -RAR receptors is disclosed. | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-07-15 | — | — | US | disclosed |
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-05-15 | — | — | US | disclosed |
| US-6506796-B1 | Cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-01-14 | — | — | US | disclosed |
| US-20010018456-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | FESUS LASZLO (HU) | 2001-08-30 | — | — | US | disclosed |
| EP-1114037-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN MEDICINES | Schering Aktiengesellschaft (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017173-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN MEDICINES | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | RARA, RARB, RARG | RARB 2/4885RARG 3/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.